"IIIM Jammu is in the process of creating a State-of-Art National Facility for small and medium scale manufacturers from north India and the state of J&K in particular to get their products manufactured under GMP/GLP conditions besides its use for research in IIIM" ...

Reserach & Development


Anti-Inflammatory & Rheumatoid Arthritis - CSIR-IIIM, Jammu has been developed a standardized drug substance (Extract) i.e., IIIM 160 A002, the manufacturing procedure has been scaled up in cGMP facility and all the manufacturing process has been optimized. Analytical method for drug substance and drug product has been developed and validated at QC/QA section. Drug product was found to be stable when stored at 30°C±2°C/65%±5%RH for 02 year in LDPE bags.

CSIR-IIIM Jammu, developed a prototype Novel drug delivery formulation (Gastro Retentive sustained release) on the standardised extract and has been granted a patent, bearing CSIR Granted No. 0120NF2017/IN. CSIR-IIIM Jammu also filled international patent for the same drug delivery formulation.

The present invention comprising an effective amount of an extract or lyophilized extract at least one bioactive fraction obtained from IIIM 160 A002 (Bergenia ciliata) along with one or more pharmaceutically acceptable additives/carriers. This invention envisages the potential of an extract obtained from the whole plant of IIIM 160 A002 (Bergenia ciliata) to act an effective therapy against Anti-inflammatory & rheumatoid arthritis.

With this background data, CSIR-IIIM, Jammu has to be compiling a dossier (IND) to the AYUSH department to conduct the Phase-I Clinical trial on Healthy volunteer through CRO.


Pasanbheda Capsules

News & Events

Useful Links

Copyright cGMP. All Rights Reserved.